Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo controlled study - PubMed (original) (raw)

Clinical Trial

Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo controlled study

K P Machold et al. Ann Rheum Dis. 1992 Sep.

Abstract

Interferon gamma (IFN gamma) has been advocated in open studies as a beneficial remission inducing drug for the treatment of rheumatoid arthritis (RA). The work reported here was designed to assess the therapeutic potential of IFN gamma in the treatment of RA in a double blind placebo controlled study. It was found that patients treated with IFN gamma improved significantly with respect to morning stiffness, grip strength, swelling of an index joint, and erythrocyte sedimentation rate. Furthermore significantly more responders (according to predetermined response criteria) were found in the group treated with IFN gamma. Only minor adverse effects and no significant toxicity with respect to clinical or laboratory parameters were observed.

PubMed Disclaimer

Similar articles

• Interferon gamma in rheumatoid arthritis--a double blind study comparing human recombinant interferon gamma with placebo.
  Veys EM, Mielants H, Verbruggen G, Grosclaude JP, Meyer W, Galazka A, Schindler J. Veys EM, et al. J Rheumatol. 1988 Apr;15(4):570-4. J Rheumatol. 1988. PMID: 3135392 Clinical Trial.
• Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma.
  Lemmel EM, Franke M, Gaus W, Hartl PW, Hofschneider PH, Miehlke K, Machalke K, Obert HJ. Lemmel EM, et al. Rheumatol Int. 1987;7(3):127-32. doi: 10.1007/BF00270465. Rheumatol Int. 1987. PMID: 3118443
• Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis.
  Cannon GW, Pincus SH, Emkey RD, Denes A, Cohen SA, Wolfe F, Saway PA, Jaffer AM, Weaver AL, Cogen L, et al. Cannon GW, et al. Arthritis Rheum. 1989 Aug;32(8):964-73. doi: 10.1002/anr.1780320805. Arthritis Rheum. 1989. PMID: 2504171 Clinical Trial.
• Thymic hormones and interferons in the treatment of rheumatoid arthritis.
  Veys EM, Mielants H, Vergruggen G. Veys EM, et al. Scand J Rheumatol Suppl. 1988;76:297-304. doi: 10.3109/03009748809102981. Scand J Rheumatol Suppl. 1988. PMID: 2472001 Review.
• Immunotherapy and other novel therapies.
  Trentham DE. Trentham DE. Curr Opin Rheumatol. 1991 Jun;3(3):369-72. doi: 10.1097/00002281-199106000-00007. Curr Opin Rheumatol. 1991. PMID: 1715732 Review.

Cited by

• Regulatory Fibroblast-Like Synoviocytes Cell Membrane Coated Nanoparticles: A Novel Targeted Therapy for Rheumatoid Arthritis.
  Liu Y, Rao P, Qian H, Shi Y, Chen S, Lan J, Mu D, Chen R, Zhang X, Deng C, Liu G, Shi G. Liu Y, et al. Adv Sci (Weinh). 2023 Feb;10(4):e2204998. doi: 10.1002/advs.202204998. Epub 2022 Dec 12. Adv Sci (Weinh). 2023. PMID: 36509660 Free PMC article.
• Positive and negative cooperativity of TNF and Interferon-γ in regulating synovial fibroblast function and B cell survival in fibroblast/B cell co-cultures.
  Lowin T, Anssar TM, Bäuml M, Classen T, Schneider M, Pongratz G. Lowin T, et al. Sci Rep. 2020 Jan 21;10(1):780. doi: 10.1038/s41598-020-57772-7. Sci Rep. 2020. PMID: 31964950 Free PMC article.
• KCa1.1 and Kv1.3 channels regulate the interactions between fibroblast-like synoviocytes and T lymphocytes during rheumatoid arthritis.
  Tanner MR, Pennington MW, Chauhan SS, Laragione T, Gulko PS, Beeton C. Tanner MR, et al. Arthritis Res Ther. 2019 Jan 7;21(1):6. doi: 10.1186/s13075-018-1783-9. Arthritis Res Ther. 2019. PMID: 30612588 Free PMC article.
• Anti-inflammatory cytokine and angiogenic factors levels in vitreous samples of diabetic retinopathy patients.
  Tsai T, Kuehn S, Tsiampalis N, Vu MK, Kakkassery V, Stute G, Dick HB, Joachim SC. Tsai T, et al. PLoS One. 2018 Mar 27;13(3):e0194603. doi: 10.1371/journal.pone.0194603. eCollection 2018. PLoS One. 2018. PMID: 29584759 Free PMC article.
• Chemotaxis of Vδ2 T cells to the joints contributes to the pathogenesis of rheumatoid arthritis.
  Mo WX, Yin SS, Chen H, Zhou C, Zhou JX, Zhao LD, Fei YY, Yang HX, Guo JB, Mao YJ, Huang LF, Zheng WJ, Zhang W, Zhang JM, He W, Zhang X. Mo WX, et al. Ann Rheum Dis. 2017 Dec;76(12):2075-2084. doi: 10.1136/annrheumdis-2016-211069. Epub 2017 Sep 2. Ann Rheum Dis. 2017. PMID: 28866647 Free PMC article.

References

1. 1. Fed Proc. 1987 Jan;46(1):113-7 - PubMed
2. 1. Arthritis Rheum. 1989 Aug;32(8):964-73 - PubMed
3. 1. Dtsch Med Wochenschr. 1985 Nov 15;110(46):1766-9 - PubMed
4. 1. Lancet. 1973 Feb 10;1(7798):275-80 - PubMed
5. 1. Lancet. 1981 Oct 17;2(8251):839-42 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • HighWire
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information